198 related articles for article (PubMed ID: 29237387)
1.
Grimaldi F; Fazio N; Attanasio R; Frasoldati A; Papini E; Cremonini N; Davi MV; Funicelli L; Massironi S; Spada F; Toscano V; Versari A; Zini M; Falconi M; Oberg K
Endocr Metab Immune Disord Drug Targets; 2018; 18(5):419-449. PubMed ID: 29237387
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view.
Fazio N; Spada F; Giovannini M
Cancer Treat Rev; 2013 May; 39(3):270-4. PubMed ID: 22819619
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.
Rinke A; Gress TM
Digestion; 2017; 95(2):109-114. PubMed ID: 28161703
[TBL] [Abstract][Full Text] [Related]
4. Metabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETs): How do they influence each other? An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper.
Natalicchio A; Faggiano A; Zatelli MC; Argentiero A; D'Oronzo S; Marrano N; Beretta GD; Acquati S; Adinolfi V; Di Bartolo P; Danesi R; Ferrari P; Gori S; Morviducci L; Russo A; Tuveri E; Montagnani M; Gallo M; Silvestris N; Giorgino F
Crit Rev Oncol Hematol; 2022 Jan; 169():103572. PubMed ID: 34954047
[TBL] [Abstract][Full Text] [Related]
5. Hormone secreting gastro-entero-pancreatic neuroendocrine neoplasias (GEP-NEN): When to consider, how to diagnose?
Fottner C; Ferrata M; Weber MM
Rev Endocr Metab Disord; 2017 Dec; 18(4):393-410. PubMed ID: 29256148
[TBL] [Abstract][Full Text] [Related]
6. Improving survival prognostication of gastroenteropancreatic neuroendocrine neoplasms: Revised staging criteria.
Martin JA; Warner RR; Wisnivesky JP; Kim MK
Eur J Cancer; 2017 May; 76():197-204. PubMed ID: 28334622
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
Fazio N; Milione M
Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
[TBL] [Abstract][Full Text] [Related]
9. Personalized treatment approach to gastroenteropancreatic neuroendocrine tumors: a medical oncologist's perspective.
Paul D; Ostwal V; Bose S; Basu S; Gupta S
Eur J Gastroenterol Hepatol; 2016 Sep; 28(9):985-90. PubMed ID: 27257869
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine neoplasms of the gastroenteropancreatic system: pathology and classification.
Anlauf M
Horm Metab Res; 2011 Nov; 43(12):825-31. PubMed ID: 22105474
[TBL] [Abstract][Full Text] [Related]
11. Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era.
Rodriguez-Freixinos V; Capdevila J; Pavel M; Thawer A; Baudin E; O'Toole D; Herrmann K; Welin S; Grozinsky-Glasberg S; de Herder WW; Valle JW; Herman J; Kolarova T; Bouvier C; Falconi M; Ferone D; Singh S
Eur J Cancer; 2021 Feb; 144():200-214. PubMed ID: 33370645
[TBL] [Abstract][Full Text] [Related]
12. Everolimus-based combination for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): biological rationale and critical review of published data.
Abdel-Rahman O; Fouad M
Tumour Biol; 2015 Feb; 36(2):467-78. PubMed ID: 25596701
[TBL] [Abstract][Full Text] [Related]
13. Systemic Treatment of Gastroenteropancreatic Neuroendocrine Carcinoma.
Mollazadegan K; Welin S; Crona J
Curr Treat Options Oncol; 2021 Jun; 22(8):68. PubMed ID: 34110508
[TBL] [Abstract][Full Text] [Related]
14. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.
Janson ET; Sorbye H; Welin S; Federspiel B; Grønbæk H; Hellman P; Ladekarl M; Langer SW; Mortensen J; Schalin-Jäntti C; Sundin A; Sundlöv A; Thiis-Evensen E; Knigge U
Acta Oncol; 2014 Oct; 53(10):1284-97. PubMed ID: 25140861
[TBL] [Abstract][Full Text] [Related]
15. Sex-Based Differences in Prognosis of Patients With Gastroenteropancreatic-Neuroendocrine Neoplasms: A Population-Based Study.
Abdel-Rahman O; Fazio N
Pancreas; 2021 May-Jun 01; 50(5):727-731. PubMed ID: 34016894
[TBL] [Abstract][Full Text] [Related]
16. Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract.
Cives M; Strosberg J
Curr Treat Options Oncol; 2017 Mar; 18(3):14. PubMed ID: 28286921
[TBL] [Abstract][Full Text] [Related]
17. [Clinical significance of new classification of gastroenteropancreatic neuroendocrine neoplasms].
Zhu XZ
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Jan; 16(1):12-4. PubMed ID: 23691561
[TBL] [Abstract][Full Text] [Related]
18. Gastroenteropancreatic neuroendocrine tumors: update on therapeutics.
Ganetsky A; Bhatt V
Ann Pharmacother; 2012 Jun; 46(6):851-62. PubMed ID: 22589450
[TBL] [Abstract][Full Text] [Related]
19. Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma.
De Divitiis C; von Arx C; Grimaldi AM; Cicala D; Tatangelo F; Arcella A; Romano GM; Simeone E; Iaffaioli RV; Ascierto PA; Tafuto S;
J Transl Med; 2016 May; 14(1):113. PubMed ID: 27142424
[TBL] [Abstract][Full Text] [Related]
20. Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy.
Teunissen JJ; Kwekkeboom DJ; de Jong M; Esser JP; Valkema R; Krenning EP
Best Pract Res Clin Gastroenterol; 2005 Aug; 19(4):595-616. PubMed ID: 16183530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]